For more detailed information regarding side effects, please refer to the appropriate product monograph.
Infusion/injection site–related reactions – sometimes managed with pre-medications.
Increased risk of serious infection (sepsis and pneumonia), invasive fungal infections, and viral infections
Approximately 10% increased risk at wk 54 Reactivation of latent TB.
Can worsen pre-existing CHF
Lupus-like reaction (rare)
Hepatocellular damage, hepatitis, jaundice, autoimmune hepatitis; reactivation of HBV
Potential increased risk of malignancy (lymphoma, hepatosplenic T-cell lymphoma, melanoma, and NMSC); Increased frequency when used in combo with a thiopurine.
Numbness and tingling in legs, arms, etc.; change in vision, weakness in legs, dizziness